![Philip Chamberlain](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Philip Chamberlain
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Neomorph, Inc.
![]() Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation. | Direktor/Vorstandsmitglied | - | - |
Vorstandsvorsitzender | - | - | |
Gründer | - | - | |
Präsident | - | - |
Karriereverlauf von Philip Chamberlain
Statistik
International
Vereinigte Staaten | 2 |
Operativ
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Founder | 1 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Neomorph, Inc.
![]() Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation. | Health Technology |
- Börse
- Insiders
- Philip Chamberlain
- Erfahrung